1. Articles in category: Genetics

    1-24 of 255 1 2 3 4 ... 9 10 11 »
    1. Genetic susceptibility to neuroblastoma: current knowledge and future directions.

      Genetic susceptibility to neuroblastoma: current knowledge and future directions.

      Cell Tissue Res. 2018 Mar 27;:

      Authors: Ritenour LE, Randall MP, Bosse KR, Diskin SJ

      Abstract Neuroblastoma, a malignancy of the developing peripheral nervous system that affects infants and young children, is a complex genetic disease. Over the past two decades, significant progress has been made toward understanding the genetic determinants that predispose to this often lethal childhood cancer.

      Read Full Article
      Mentions: ALK PHOX2B
    2. A rare mediastinal occurrence of neuroblastoma in an adult: case report.

      A rare mediastinal occurrence of neuroblastoma in an adult: case report.

      Sao Paulo Med J. 2018 Mar 05;:0

      Authors: Yanik F, Karamustafaoglu YA, Yoruk Y

      Abstract CONTEXT: Neuroblastoma is the most common extracranial malignant solid tumor that occurs during childhood. It arises from primitive cells and is seen in the adrenal medulla and sympathetic ganglia of the sympathetic nervous system.

      Read Full Article
    3. The mutational landscape of MYCN, Lin28b and ALKF1174L driven murine neuroblastoma mimics human disease.

      The mutational landscape of MYCN, Lin28b and ALKF1174L driven murine neuroblastoma mimics human disease.

      Oncotarget. 2018 Feb 02;9(9):8334-8349

      Authors: De Wilde B, Beckers A, Lindner S, Kristina A, De Preter K, Depuydt P, Mestdagh P, Sante T, Lefever S, Hertwig F, Peng Z, Shi LM, Lee S, Vandermarliere E, Martens L, Menten B, Schramm A, Fischer M, Schulte J, Vandesompele J, Speleman F

      Read Full Article
      Mentions: ALK MYCN
    4. A molecular map of childhood cancers

      A molecular map of childhood cancers

      Researchers led by Professor Stefan Pfister from the “Hopp Children’s Cancer Center at the NCT Heidelberg” (KiTZ) have been able to draw an extremely detailed molecular map of childhood cancers. In close collaboration with the German Cancer Consortium (DKTK) and the Society for Pediatric Oncology and Hematology (GPOH), they screened almost 1,000 tumor samples from […]

      The post A molecular map of childhood cancers appeared first on Healthcanal.com.

      Read Full Article
      Mentions: GPOH Genetics
    5. Association between NEFL Gene Polymorphisms and Neuroblastoma Risk in Chinese Children: A Two-Center Case-Control Study.

      Association between NEFL Gene Polymorphisms and Neuroblastoma Risk in Chinese Children: A Two-Center Case-Control Study.

      J Cancer. 2018;9(3):535-539

      Authors: Wu Q, Zhuo ZJ, Zeng J, Zhang J, Zhu J, Zou Y, Zhang R, Yang T, Zhu D, He J, Xia H

      Abstract Neuroblastoma is a lethal tumor that mainly occurs in children. To date, the genetic etiology of sporadic neuroblastoma remains obscure.

      Read Full Article
    6. Whole exome sequencing reveals novel somatic alterations in neuroblastoma patients with chemotherapy.

      Whole exome sequencing reveals novel somatic alterations in neuroblastoma patients with chemotherapy.

      Cancer Cell Int. 2018;18:21

      Authors: Duan C, Wang H, Chen Y, Chu P, Xing T, Gao C, Yue Z, Zheng J, Jin M, Gu W, Ma X

      Abstract Background: We ought to explore the acquired somatic alterations, shedding light on genetic basis of somatic alterations in NB patients with chemotherapy.

      Read Full Article
      Mentions: Chemotherapy
    7. Investigation of major genetic alterations in neuroblastoma.

      Investigation of major genetic alterations in neuroblastoma.

      Mol Biol Rep. 2018 Feb 17;:

      Authors: Costa RA, Seuánez HN

      Abstract Neuroblastoma (NB) is the most common extracranial solid tumor in childhood. This malignancy shows a wide spectrum of clinical outcome and its prognosis is conditioned by manifold biological and genetic factors.

      Read Full Article
      Mentions: INRG MYCN
    8. Origin and initiation mechanisms of neuroblastoma.

      Origin and initiation mechanisms of neuroblastoma.

      Cell Tissue Res. 2018 Feb 14;:

      Authors: Tsubota S, Kadomatsu K

      Abstract Neuroblastoma is an embryonal malignancy that affects normal development of the adrenal medulla and paravertebral sympathetic ganglia in early childhood. Extensive studies have revealed the molecular characteristics of human neuroblastomas, including abnormalities at genome, epigenome and transcriptome levels.

      Read Full Article
    9. PIM kinases are a potential prognostic biomarker and therapeutic target in neuroblastoma.

      PIM kinases are a potential prognostic biomarker and therapeutic target in neuroblastoma.

      Mol Cancer Ther. 2018 Feb 13;:

      Authors: Brunen D, de Vries RC, Lieftink C, Beijersbergen RL, Bernards R

      Abstract The majority of high-risk neuroblastoma patients are refractory to, or relapse on current treatment regimens, resulting in 5-year survival rates of less than 50%. This emphasizes the urgent need to identify novel therapeutic targets.

      Read Full Article
    10. A highly malignant case of neuroblastoma with substantial increase of single-nucleotide variants and normal mismatch repair system: A case report.

      A highly malignant case of neuroblastoma with substantial increase of single-nucleotide variants and normal mismatch repair system: A case report.

      Medicine (Baltimore). 2017 Dec;96(50):e8845

      Authors: Yuan LQ, Wang JH, Zhu K, Yang M, Gu WZ, Lai C, Li HM, Shu Q, Chen X

      Read Full Article
    11. Biological and Genetic Features of Neuroblastoma and Their Clinical Importance.

      Biological and Genetic Features of Neuroblastoma and Their Clinical Importance.

      Curr Pediatr Rev. 2018 Jan 28;:

      Authors: Aygun N

      Abstract Neuroblastoma derived from primitive cells of the sympathetic nervous system typically develops in the adrenal medulla or paraspinal ganglia. Neuroblastoma usually occurs sporadically, but familial cases are also observed.

      Read Full Article
      Mentions: ALK MYCN PHOX2B
    12. 'Hijacker' drives cancer in some patients with high-risk neuroblastoma

      Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome “hijacks” DNA that regulates other genes. The resulting insights may help scientists develop more effective therapies, including ...

      Read Full Article
    13. Epigenetic regulation of neuroblastoma development.

      Epigenetic regulation of neuroblastoma development.

      Cell Tissue Res. 2018 Jan 19;:

      Authors: Kaat D, Frank S

      Abstract In recent years, technological advances have enabled a detailed landscaping of the epigenome and the mechanisms of epigenetic regulation that drive normal cell function, development and cancer.

      Read Full Article
    14. Identification of the genetic and clinical characteristics of neuroblastomas using genome-wide analysis.

      Identification of the genetic and clinical characteristics of neuroblastomas using genome-wide analysis.

      Oncotarget. 2017 Dec 08;8(64):107513-107529

      Authors: Uryu K, Nishimura R, Kataoka K, Sato Y, Nakazawa A, Suzuki H, Yoshida K, Seki M, Hiwatari M, Isobe T, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Koh K, Hanada R, Oka A, Hayashi Y, Ohira M, Kamijo T, Nagase H, Takimoto T, Tajiri T, Nakagawara A, Ogawa S, Takita J

      Read Full Article
      Mentions: ALK MYCN
    15. Coexpression network analysis identifies transcriptional modules associated with genomic alterations in neuroblastoma.

      Coexpression network analysis identifies transcriptional modules associated with genomic alterations in neuroblastoma.

      Biochim Biophys Acta. 2017 Dec 13;:

      Authors: Yang L, Li Y, Wei Z, Chang X

      Abstract Neuroblastoma is a highly complex and heterogeneous cancer in children. Acquired genomic alterations including MYCN amplification, 1p deletion and 11q deletion are important risk factors and biomarkers in neuroblastoma.

      Read Full Article
      Mentions: MYCN Biomarkers
    16. Researchers identify an indirect way of countering a key genetic lesion in neuroblastoma

      Researchers identify an indirect way of countering a key genetic lesion in neuroblastoma

      Pediatric cancers tend to have relatively "quiet" genomes compared to tumors in adults. They harbor fewer discrete genetic mutations, especially in genes for readily "druggable" targets (such as protein kinases). Instead, these tumors tend to feature other kinds of genetic alterations, such as duplications or translocations.

      Read Full Article
      Mentions: MYCN
    17. CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2.

      CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2.

      J Clin Invest. 2017 Dec 04;:

      Authors: Chen L, Alexe G, Dharia NV, Ross L, Iniguez AB, Conway AS, Wang EJ, Veschi V, Lam N, Qi J, Gustafson WC, Nasholm N, Vazquez F, Weir BA, Cowley GS, Ali LD, Pantel S, Jiang G, Harrington WF, Lee Y, Goodale A, Lubonja R, Krill-Burger JM, Meyers RM, Tsherniak A, Root DE, Bradner JE, Golub TR, Roberts CW, Hahn WC, Weiss WA, Thiele CJ, Stegmaier K

      Read Full Article
      Mentions: MYCN
    18. MYCN Amplification Is Associated with Repressed Cellular Immunity in Neuroblastoma: An In Silico Immunological Analysis of TARGET Database.

      MYCN Amplification Is Associated with Repressed Cellular Immunity in Neuroblastoma: An In Silico Immunological Analysis of TARGET Database.

      Front Immunol. 2017;8:1473

      Authors: Zhang P, Wu X, Basu M, Dong C, Zheng P, Liu Y, Sandler AD

      Abstract Purpose: RNA and DNA sequencing data are traditionally used to discern intrinsic cellular pathways in cancer pathogenesis, their utility for investigating the tumor microenvironment (TME) has not been fully explored.

      Read Full Article
      Mentions: MYCN
    19. Loss of DNA Damage Response in Neuroblastoma and Utility of a PARP Inhibitor.

      Loss of DNA Damage Response in Neuroblastoma and Utility of a PARP Inhibitor.

      J Natl Cancer Inst. 2017 Nov 01;109(11):

      Authors: Takagi M, Yoshida M, Nemoto Y, Tamaichi H, Tsuchida R, Seki M, Uryu K, Nishii R, Miyamoto S, Saito M, Hanada R, Kaneko H, Miyano S, Kataoka K, Yoshida K, Ohira M, Hayashi Y, Nakagawara A, Ogawa S, Mizutani S, Takita J

      Read Full Article
    20. Genetic Variations of GWAS-Identified Genes and Neuroblastoma Susceptibility: a Replication Study in Southern Chinese Children.

      Genetic Variations of GWAS-Identified Genes and Neuroblastoma Susceptibility: a Replication Study in Southern Chinese Children.

      Transl Oncol. 2017 Oct 09;10(6):936-941

      Authors: He J, Zou Y, Wang T, Zhang R, Yang T, Zhu J, Wang F, Xia H

      Abstract Neuroblastoma is one of the most commonly diagnosed solid cancers for children, and genetic factors may play a critical role in neuroblastoma development.

      Read Full Article
    21. Study Identifies Patients Who Benefit Most From Dinutuximab-based Immunotherapy

      Using data from a randomized phase III clinical trial of neuroblastoma patients (treated with or without immunotherapy) performed by the Children’s Oncology Group, researchers from the University of Wisconsin School of Medicine and Public Health found that a subset of patients, identified by the presence of a certain set of genes, were more likely to benefit from […]

      The post Study Identifies Patients Who Benefit Most From Dinutuximab-based Immunotherapy appeared first on Healthcanal.com.

      Read Full Article
      Mentions: Immunotherapy
    1-24 of 255 1 2 3 4 ... 9 10 11 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles

  3. Researches in the News

    1. (1 articles) ALK
    2. (1 articles) PHOX2B